MX2021011748A - IFNß COMO UN MARCADOR FARMACODINÁMICO EN LA TERAPIA ONCOLÍTICA DE VSV-IFNß-NIS. - Google Patents

IFNß COMO UN MARCADOR FARMACODINÁMICO EN LA TERAPIA ONCOLÍTICA DE VSV-IFNß-NIS.

Info

Publication number
MX2021011748A
MX2021011748A MX2021011748A MX2021011748A MX2021011748A MX 2021011748 A MX2021011748 A MX 2021011748A MX 2021011748 A MX2021011748 A MX 2021011748A MX 2021011748 A MX2021011748 A MX 2021011748A MX 2021011748 A MX2021011748 A MX 2021011748A
Authority
MX
Mexico
Prior art keywords
ifnbeta
vsv
nis
pharmacodynamic marker
oncolytic therapy
Prior art date
Application number
MX2021011748A
Other languages
English (en)
Inventor
Luke Russell
Kah-Whye Peng
Stephen James Russell
Original Assignee
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res
Publication of MX2021011748A publication Critical patent/MX2021011748A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/565—IFN-beta
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)

Abstract

La presente invención se refiere en general a marcadores farmacocinéticos y farmacodinámicos para regímenes terapéuticos de cáncer y métodos para tratar el cáncer. Se proporcionan sondas de virus oncolíticos que comprenden un ácido nucleico que codifica para interferón beta soluble (IFNß) y métodos para uso de éstos.
MX2021011748A 2019-03-28 2020-03-27 IFNß COMO UN MARCADOR FARMACODINÁMICO EN LA TERAPIA ONCOLÍTICA DE VSV-IFNß-NIS. MX2021011748A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825482P 2019-03-28 2019-03-28
PCT/US2020/025409 WO2020198652A1 (en) 2019-03-28 2020-03-27 Ifnbeta as a pharmacodynamic marker in vsv-ifnbeta-nis oncolytic therapy

Publications (1)

Publication Number Publication Date
MX2021011748A true MX2021011748A (es) 2022-01-24

Family

ID=72608948

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011748A MX2021011748A (es) 2019-03-28 2020-03-27 IFNß COMO UN MARCADOR FARMACODINÁMICO EN LA TERAPIA ONCOLÍTICA DE VSV-IFNß-NIS.

Country Status (12)

Country Link
US (1) US20220178910A1 (es)
EP (1) EP3946421A4 (es)
JP (1) JP2022527631A (es)
KR (1) KR20220008810A (es)
CN (1) CN113924110A (es)
AU (1) AU2020244878A1 (es)
CA (1) CA3134957A1 (es)
EA (1) EA202192645A1 (es)
IL (1) IL286724A (es)
MX (1) MX2021011748A (es)
SG (1) SG11202110697UA (es)
WO (1) WO2020198652A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951117B2 (en) * 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
AU2013211871B2 (en) * 2012-01-25 2017-12-14 Board Of Regents, The University Of Texas System Biomarkers and combination therapies using oncolytic virus and immunomodulation
US11865149B2 (en) * 2016-06-17 2024-01-09 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
FI20165814A (fi) * 2016-10-27 2018-04-28 Tilt Biotherapeutics Oy Interleukiini 8 (il-8) prognostisena ja ennustavana biomarkkerina ja koostumukset ja vektorit käytettäväksi onkolyyttisessa immunoterapiassa
WO2018132571A1 (en) * 2017-01-13 2018-07-19 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer

Also Published As

Publication number Publication date
KR20220008810A (ko) 2022-01-21
CN113924110A (zh) 2022-01-11
WO2020198652A1 (en) 2020-10-01
IL286724A (en) 2021-10-31
EA202192645A1 (ru) 2022-01-13
AU2020244878A1 (en) 2021-10-21
US20220178910A1 (en) 2022-06-09
EP3946421A4 (en) 2022-12-21
EP3946421A1 (en) 2022-02-09
SG11202110697UA (en) 2021-10-28
CA3134957A1 (en) 2020-10-01
JP2022527631A (ja) 2022-06-02

Similar Documents

Publication Publication Date Title
ZA202002094B (en) Trispecific proteins and methods of use
IL280844A (en) Transducer arrays with improved flexibility to provide tumor treating fields
IL280350A (en) Systems and methods for producing gene therapy formulations
FI20115914L (fi) Muunnettu onkolyyttinen virus
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2021001158A (es) Vector hsv oncolitico.
EP4021559C0 (en) DELIVERY OF TUMOR TREATMENT FIELDS (TTFIELDS) TO THE NECK
MX2018005468A (es) Terapia dirigida contra el cáncer.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
PH12017501031A1 (en) Methods and compositions for treating cancer
MX2017006910A (es) Nuevos indazoles sustituidos, procedimientos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos.
MX2016010683A (es) Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2.
NZ739503A (en) A novel approach for treatment of cancer using immunomodulation
BR112018069944A2 (pt) construto de rna e métodos de uso do mesmo para melhorar os efeitos terapêuticos de células citotóxicas e células-tronco
SG11202107922QA (en) Closed-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response
MX2018010288A (es) Sistema de transposon y metodos de uso.
IL284645A (en) Therapeutic RNA and Anti PD1 antibodies for the treatment of solid cancer tumors in advanced stages
MX2017011633A (es) Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas.
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
TW201614237A (en) Markers for identifying patients responsive to anti-PD-L1 antibody therapy
IN2014MN02105A (es)
MX2017011600A (es) Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
EP3969120A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF TREATING CANCER IN COMBINATION WITH INTERLEUKIN PROTEIN ANALOGS